Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003565 · ClinicalTrials.gov registry record · Phase 2
Docetaxel in Treating Patients With Solid Tumors
A Phase 2 study of Breast Cancer and Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 20
- Study locations
NCT00003565: Completed Phase 2 study of Breast Cancer and Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00003565 is a Phase 2 study of Breast Cancer and Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 109 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003565, a Phase 2 study of Breast Cancer and Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American patients who have solid tumors.
Conditions Studied
Interventions
- DRUG docetaxel
Study Locations (20)
Illinois
- MBCCOP - University of Illinois at Chicago - Chicago
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- West Suburban Center for Cancer Care - River Forest
- Saint Anthony Medical Center - Rockford
Florida
- Broward General Medical Center - Fort Lauderdale
- Memorial Regional Hospital Comprehensive Cancer Center - Hollywood
- CCOP - Mount Sinai Medical Center - Miami Beach
- Florida Hospital Cancer Institute - Orlando
- Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center - West Palm Beach
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Veterans Affairs Medical Center - San Diego - San Diego
- UCSF Comprehensive Cancer Center - San Francisco
- Veterans Affairs Medical Center - San Francisco - San Francisco
District of Columbia
- Lombardi Cancer Center - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
- Veterans Affairs Medical Center - Washington, DC - Washington D.C.
Alabama
- Northeast Alabama Regional Medical Center - Anniston
Delaware
- CCOP - Christiana Care Health Services - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 1998-09 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
What the finished NCT00003565 record still lists
NCT00003565 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which docetaxel is the first listed.
NCT00003565 names 20 study sites across 6 states, led by Illinois, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00003565 about?
NCT00003565 is a clinical study titled "Docetaxel in Treating Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American patients who have solid tumors.
What is the current status of trial NCT00003565?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 1998-09. Estimated completion is 2008-01.
What conditions does trial NCT00003565 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Head and Neck Cancer, Bladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00003565?
The interventions under investigation include: docetaxel (DRUG).
Who is sponsoring clinical trial NCT00003565?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003565 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003565's enrollment target sits among peer trials
109 542nd of 1224 higher than 683 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia